

### <u>ICARUS-LUNG01</u>: A phase 2 Study of Dato-DXd in patients with previously treated advanced NSCLC, with sequential tissue biopsies and biomarkers analysis to predict treatment outcome

**D. Planchard<sup>1,2</sup>**, N. Cozic<sup>3</sup>, M. Wislez<sup>4</sup>, C. Chouaid<sup>5</sup>, H. Curcio<sup>6</sup>, S. Cousin<sup>7</sup>, C. Mascaux<sup>8</sup>, J. Cadranel<sup>9</sup>, M. Geier<sup>10</sup>, M. R. Ghigna<sup>11</sup>, G. Nachabeh<sup>12</sup>, R. Zwirtes<sup>13</sup>, R. Chiaverelli<sup>13</sup>, R. Cheikh-Hussin<sup>14</sup>, N. Corcos<sup>14</sup>, F. Mosele<sup>1,15</sup>, F. André<sup>1,2,15</sup>, G. Montagnac<sup>14</sup>, B. Pistilli<sup>1,14</sup>

1Department of Medical Oncology, Gustave Roussy, Villejuif, France; 2Faculty of Medicine, Paris-Saclay University, Paris, France; 3Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; 4Department of Pulmonology-Thoracic Oncology, Cochin Hospital, Paris, France; 5Department of Pulmonology, Centre Hospitalier Intercommunal de Créteil, Créteil, France; 6Department of Medical Oncology, Centre François Baclesse, Caen, France; 7Department of Medical Oncology, Institut Bergonié, Regional Comprehensive Cancer, Bordeaux, France; 8Department of Pulmonology, Nouvel Hopital Civil, Strasbourg University Hospital, Strasbourg, France; 9Sorbonne University, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Service de pneumologie et Centre Constitutif des Maladies Pulmonaires Rares, Paris, France; 10Department of Medical Oncology, Regional University Hospital, Brest, France; 11Department of Pathology, Gustave Roussy, Villejuif, France; 12Projects and Promotion Division, Gustave Roussy, Villejuif, France; 13Daiichi-Sankyo Inc, NJ, USA; 14INSERM U1279, Gustave Roussy, Villejuif, France; 15INSERM U981, Gustave Roussy, Villejuif, France



2024 ASCC

annliai mfftin








# Background

2024 ASC

ANNLIAI MEETI

- Few treatments with limited benefit are currently available after failure of platinum-based chemotherapy, immunotherapy, and targeted therapies in patients with advanced NSCLC<sup>1</sup>
- TROP2 is a transmembrane glycoprotein overexpressed in around 80% of NSCLC; high TROP2 expression was associated with poor prognosis in patients with adenocarcinomas, but not in patients with SCC<sup>2</sup>
- Currently, no TROP2 directed therapies are approved for NSCLC
- Datopotamab deruxtecan (Dato-DXd) is a nextgeneration ADC, composed of a TROP2-directed monoclonal antibody linked to a topoisomerase I inhibitor via a cleavable peptide linker<sup>3</sup>



Topoisomerase I inhibitor payload (DXd)

NSCLC: Non-Small Cell Lung Cancer, TROP2: Trophoblast Cell Surface Protein 2, SCC: Squamous-Cell Carcinoma, ADC: Antibody-Drug Conjugate

PRESENTED BY:

#ASCO24

1. Besse, B. et al. (2024). Nat Med 30(3),716–729; 2. Inamura, K. et al. (2017). Oncotarget 8(17),28725-28735; 3. Okajima, D. et al. (2018). JCO 36(15\_suppl),24206-24206.




Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

D. Planchard, MD. PhD

# Background

 The phase 3 TROPION-Lung01 study demonstrated a statistically significant improvement in PFS with Dato-DXd over docetaxel (HR: 0.75, p = 0.004) in patients with previously treated, advanced/metastatic NSCLC, with a PFS benefit mostly driven by patients with non-squamous histology<sup>1</sup>



- Dato-DXd showed clinically meaningful OS improvement vs. docetaxel in patients with non-squamous histology<sup>2</sup>
- Biomarkers of response and resistance to Dato-DXd are currently under investigation<sup>3</sup>

1. Ahn M-J, et al. (2023). Annals of Oncology 34(Suppl 2),S1305-S1306; 2. Astrazeneca, Media, www.astrazeneca-us.com/media/pressreleases/2024/datopotamab-deruxtecan-showed-clinically-meaningful-overall-survival-improvement-vs-chemotherapy-in-patients-with-advancednonsquamous-non-small-cell-lung-cancer-in-tropion-lung01-phase-iii-trial.html, updated on 27 May 2024 3. Shastry M; et al; (2022); Breast 66,169-177



PFS: Progression-Free Survival, OS: Overall Survival

#ASCO24






## Background


2024 ASCO

ANNUAL MEETING

#ASCO24







#### **Primary Endpoint:** Investigator-assessed ORR\*

#### **Secondary Endpoints:**

- DOR, PFS, CBR, OS
- Safety and tolerability

### **Exploratory Endpoints:**

- Predictors of response/resistance
- Dynamics of TROP2 expression before and after treatment
- CTCs levels during treatment

ECOG PS: Eastern Cooperative Oncology Group Performance Status, FFPE: Formalin-Fixed Paraffin-Embedded, Q3W: every 3 weeks, PD: Progressive Disease, C: Cycle, D: Day, EOT: End of Treatment; ORR: Objective Response Rate, DOR: Duration of Response, CBR: Clinical Benefit Rate, CTCs: Circulating Tumor Cells

Dato-DXd 6 mg/kg Q3W

until PD or unacceptable toxicity

\* Confirmed ORR as per RECIST V1.1 assessment every 6 weeks until objective progressive disease



PRESENTED BY: D. Planchard, MD. PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



### Multi-center, single-arm, phase 2 study (NCT04940325)



### Mandatory sample collection :

ICARUS-Lung01

**KEY ELIGIBILITY CRITERIA** 

ECOG PS of 0 or 1

NSCLC (stage IIIB, IIIC, or IV)

Progressed on prior 1-3 lines:

Without known mutations: anti PD-1/PDL-1

containing therapy and a platinum-doublet regimen

With known EGFR, BRAF, MET ALK, ROS1, RET,

**Study Design** 

Tumor biopsy (1 Frozen + 3 FFPE)

#ASCO24

Blood (5 to 69 ml)

# Statistical considerations and methods



- Investigator-initiated, multi-center trial in 8 French sites
- **Primary endpoint:** confirmed ORR according to the investigator Evaluation RECIST (V1.1) every 6 weeks
- Sample size: H0: ORR ≤ 10%; 100 patients included and evaluable to achieve 87% power to test H₀ at a one-sided 5% significance level, assuming H1: ORR = 20%
- **Data cut-off:** Apr 18<sup>th</sup>, 2024





#ASCO24

# **Demographics and baseline characteristics**



PATIENTS N=100			
Age Median (range), years	60 (26;83)	PD-L1 available, n (%)	84 (84)
	00 (20,00)	– PD-L1 <1 % (Negative)	45 (54)
Sex, n (%)		PD-L1 1- 49%	25 (30)
Male	62 (62)	PD-L1 ≥ 50%	14 (16)
Female	38 (38)	Unknown PD-L1	16 (16)
Smoking history, n (%)		Brain metastases at baseline, n (%)	
Never smoker	10 (10)	Dram metastases at basenne, n (70)	
Current/former smoker	89 (89)	No	93 (93)
Histology, n (%)		Yes	7 (7)
Non-squamous	82 (82)	Prior lines of therapy, n (%)	
Squamous	18 (18)		
•		- 1	23 (23)
Genomic alterations available, n (%)	85 (85)	2	50 (50)
Present	60 (71)	≥ 3	27 (27)
EGFR <sup>a</sup>	11 (18.3)	Prior systemic therapy, n (%)	
BRAFV600E	1 (1.7)		
Absent	25 (29)	Platinum-based chemotherapy	98 (98)
		Prior anti PD-L1	89 (89)
Unknown genomic alterations	15 (15)	Targeted therapy	17 (17)

<sup>a</sup>EGFR exon 19, exon 20 or exon 21

#ASCO24





### **Patient disposition**




PATIENTS N=100				
Dato-DXd treatment status, n (%)				
Ongoing	6 (6)			
Discontinued	94 (94)			
Primary reason for discontinuation, n (%)				
Disease progression	77 (77)			
Adverse events	11 (11)			
Other	6 (6)			
Number of Dato-DXd cycles, median (range)	5 (1; 35)			
Median treatment duration, months (range)	3.5 (0.7; 25.8)			
At least one dose modification, n (%)				
No	74 (74)			
Yes	26 (26)			

100 patients were enrolled in 8 French sites between Jun 9<sup>th</sup>, 2021 and Jul13<sup>th</sup>, 2022 Data cut-off date: Apr 18<sup>th</sup>, 2024





# **ORR: overall population and by subgroups**



Overall population, N=100		
Confirmed ORR <sup>a</sup> , %         26.           [95%CI]         [17.4 ;		
DOR, median (months)	<b>7.0</b>	
[95%Cl]	[5.5 ; 11.9]	
<b>CBR</b> <sup>b</sup> <b>, %</b>	<b>36</b>	
[95%CI]	[26.6 ; 45.4]	

#### **ORR** by histology (N=100)/genomic alterations (N=85)

ORR by	NSQ (N=82)	SCC (N=18)
histology, %	30.5	5.6
<sup>[95%CI]</sup>	[20.8 ; 41.6]	[0.14 ; 27.3]
ORR by EGFR,	Present (N=12)	Absent (N=73)
BRAF mut <sup>c</sup> , %	50.0	23.2
<sup>[95%CI]</sup>	[21.1 ; 78.9]	[14.2 ; 34.7]

H0 : p0 ≤10% is rejected, p value<.0001

KRAS mut<sup>d</sup> (N=11) ORR: 63.6% [30.8; 89.1%] KRAS wt (N=74) ORR: 21.6% [12.9; 32.7%]

NSQ: Non-Squamous Cell Carcinoma

#ASCO24

<sup>a</sup>Confirmed ORR; clopper-Pearson (Exact) method was used for confidence interval; <sup>b</sup>Defined as the presence of  $\geq$  1 partial or complete response, or a stable disease for >6 months under treatment, <sup>c</sup>11 EGFR: exon 19, 20, 21; 1 BRAFV600E; <sup>d</sup>KRAS G12C (n=7)




PRESENTED BY: D. Planchard, MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



CARUS

# **PFS: overall population and by histology**



\*Regardless of histology



#ASCO24

PRESENTED BY: D. Planchard, MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



## **Overall safety data**



Overall safety profile, n (%)		
<ul> <li>Patients with any grade TEAEs</li> </ul>	95 (95.0)	
Grade ≥3 TEAEs	50 (50.0)	
<ul> <li>Patients with any grade TRAEs</li> </ul>	88 (88.0)	
Grade ≥3 TRAEs	24 (24.0)	
<ul> <li>Leading to Dato-DXd discontinuation</li> </ul>	18 (18.0)	
<ul> <li>Leading to Dato-DXd interruption</li> </ul>	18 (18.0)	
<ul> <li>Leading to Dato-DXd dose reduction</li> </ul>	12 (12.0)	
<ul> <li>Leading to death</li> </ul>	3 (3.0)*	
<ul> <li>Adjudicated treatment-related ILD</li> </ul>	1 (1.0)**	

TRAEs occurring in ≥ 10% of patients			
	Any grade, n (%)	Grade ≥ 3	
Stomatitis	48 (48)	11 (11)	
Nausea	47 (47)	0	
Alopecia	38 (38)	0	
Fatigue	33 (33)	2 (2)	
Constipation	18 (18)	1 (1)	
General disorders and administration site conditions	15 (15)	0	
Anorexia	12 (12)	0	
Diarrhea	11 (11)	0	
Vomiting	12 (12)	2 (2)	
Ocular event	11 (11)	1 (1)	
Dry skin	9 (9)	0	

TEAEs: Treatment-Emergent Adverse Events; TRAEs: Treatment-Related Adverse Events; ILD: Interstitial Lung Disease

\*3 patients had grade 5 toxicities probably related to study treatment: 2 pneumopathies, 1 hepatobiliary disorder

\*\*Among the 8 cases identified as suspected during the treatment period, 1 case was adjudicated as a confirmed ILD, grade 1




#ASCO24



## **Exploratory biomarker analyses**






§§ analysis at progression are ongoing and 6 patients are still on-treatment





ASCO<sup>®</sup> AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

# **Exploratory biomarker analyses**



\*n = 10 non-available samples; n = 9 samples non-analyzable due to lack of tumor cellularity \*\*n =37 excluded: 0 % tumor cellularity or not pass quality control; n = 29 not available on site or not collected \*\*\*n =24 excluded: 0 % tumor cellularity or not pass quality control; n = 29 not available on site or not collected § n = 32 excluded: 0 % tumor cellularity or not pass quality control only FFPE samples available; n = 34 not available on site or not collected; §§ analysis at progression are ongoing and 6 patients are still on-treatment

IHC: Immunohistochemistry, RNAseq: RNA Sequencing, IMC: Imaging Mass Cytometry, WES: Whole Exome Sequencing






Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



CARUS

# **Exploratory biomarker analyses**



\*\*\*n=24 excluded: 0 %tumor cellularity or not pass quality control; n=29 not available on site or not collected § n= 32 excluded: 0 % tumor cellularity or not pass quality control only FFPE samples available; n = 34 not available on site or not collected; §§ analysis at progression are ongoing and 6 patients are still on-treatment

IHC: Immunohistochemistry, RNAseq: RNA Sequencing, IMC: Imaging Mass Cytometry, WES: Whole Exome Sequencing





C2D1, EOT)

#ASCO24


Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



CARU

# **TROP2 expression and PFS**





Of the 78 patients with H-Score available at baseline, 3 were omitted due to lack of	
tumor cells (% of tumor cells < 10%).	

#ASCO24





Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

TROP2	<100	100-200	≥200
(H-score)*	(N = 13)	(N = 22)	(N = 40)
Median PFS, months	<b>2.0</b>	<b>6.1</b>	<b>3.5</b>
[95% Cl]	[0.7 ; 2.2]	[2.1 ; 9.2]	[2.6 ; 5.5]
HR**	ref	<b>0.37</b>	<b>0.50</b>
[95% CI]		[0.18-0.75]	[0.26-0.94]

\*TROP2 (EPR20043) FLA IHC; H-Score: autocalculation of tumor cells staining intensity in the membrane compartment= (1\*[MEMBRANE 1+]) + (2\*[MEMBRANE 2+]) + (3\*[MEMBRANE 3+]) \*\*p value = 0.02

### Patients with a wide range of **TROP2** expression may benefit from Dato-DXd §

<sup>§</sup> No statistically significant association with ORR



# **Genomic alterations and treatment response**

Matched DNA


47 frozen tissue biopsies at <u>baseline</u> analyzed by WES\*

12

2024 ASCO

ANNUAL MEETING

- Driver events (point mutations, indels, homozygous deletions / high-level amplifications, CNA) in genes altered in at least 2 biopsies at baseline\*\*
- 5 pairs of <u>baseline/EoT</u> tissue biopsies analyzed by WES\*\*\*
- Alterations (point mutations, indels, homozygous deletions/ highlevel amplifications, CNA) in 75 pre-defined genes of interest including known driver mutations in NSCLC




### No driver alteration presented significant association with response/resistance to Dato-DXd

\*47/71 samples at baseline passed quality check control of exome capture; \*\* " Point muts. and indels were identified with Mutect2 following best practices while CNAs were called with FACETS. Only focal CNAs (segment size < 10 Mb) and only point muts. and indels with a VAF > 5% were analyzed. This criteria was relaxed in case the alteration was identified in another matched sample. Fisher tests were performed to assess association between altered/not altered and responders/non-responders. "P\_Value\_Adj" by Benjamini-Hochberg method; \*\*\*5 patients had analyzable pairs at baseline and EoT; sample collection and analysis at progression are still ongoing



CARUS



PRESENTED BY:

#ASCO24


#### Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

D. Planchard, MD. PhD

# Gene expression modulation by Dato-DXd



- 17 pairs of baseline/on-treatment biopsies<sup>§</sup> from <u>all analyzable samples</u>, <u>regardless response to treatment</u> analyzed by bulk RNA-seq
- <u>GENE SET ENRICHMENT ANALYSIS (GSEA)</u>: 40 pre-defined pathways of interest (Wiki). "P\_Value\_Adj" by Benjamini-



### ACTIVATION OF DNA REPAIR AND SUPPRESSION OF IMMUNE RELATED PATHWAYS WITH Dato-DXd (adj p-value <0.05)

§Samples at C1D3 or C2D3 selected by: Tumor cellularity ≥ 30%; Quantity > 250 ng; RNA integrity number > 2; Filter reads > 15M






# **Gene expression modulation by Dato-DXd**



- 14 pairs of baseline/on-treatment biopsies\* from <u>non-responders</u><sup>§</sup> patients analyzed by bulk RNA-seq
- GENE SET ENRICHMENT ANALYSIS (GSEA): 40 pre-defined pathways of interest (Wiki). "P\_Value\_Adj" by Benjamini-Hochberg method



### ACTIVATION OF DNA REPAIR AND SUPPRESSION OF IMMUNE RELATED PATHWAYS WITH Dato-DXd IN NON RESPONDERS (*adj p-value <0.05*)

\*Samples selected by: Tumor cellularity ≥30%; Quantity >250 ng; RNA integrity number >2; Filter reads>15M; <sup>§</sup> Data on responders not presented as only 3 pairs of baseline/on-treatment biopsies were analyzable among responders





# **Conclusions and perspectives**

 In this pretreated population, Dato-DXd showed similar efficacy and safety results to those reported in TROPION-Lung01

• Patients with non-squamous histology, appeared to derive the greatest benefit (ORR: 30.5%; mPFS: 4.8mo)

- Patients with a wide range of TROP2 expression may benefit from Dato-DXd. In this study, patients with TROP2 of H-Score ≥ 100 seem to derive the greatest clinical benefit (H-score <100: n=13)</li>
- Although with the limitations of the small sample size:
  - No genomic driver alterations at baseline seem associated with response/resistance to Dato-DXd
  - Activation of DNA repair and suppression of immune-related pathways after 1-2 cycles of Dato-DXd could be associated with treatment resistance
- Further biomarker analysis are ongoing: genomic analysis at progression, TROP-2 spatial distribution (AI-digital pathology), immune-modulation and Dato-DXd internalization (IMC), along with CTC, ctDNA

AI: Artificial Intelligence





# Acknowledgements

- We thank the patients who participated in the study, their families and caregivers
- We thank all the investigators and study members
- This study is sponsored by Gustave Roussy Cancer Center and supported by Daiichi-Sankyo





- Gustave Roussy
- Hôpital Cochin
- · Centre Hospitalier Intercommunal de Créteil
- Centre François Baclesse
- Institut Bergonié
- Hopitaux Universitaires de Strasbourg
- Hôpital Tenon
- Institut de cancérologie, Centre Hospitalier Régional Universitaire Morvan de Brest





D. Planchard, MD, PhD

PRESENTED BY: